Portfolio - o2h Ventures

o2h ventures has so far invested in 25 promising early stage biotech companies in the UK from the Human Health EIS fund as well as angel investments.

Enedra Therapeutics Ltd

Developing the first personalised medicines that treat heterogeneous cancers, a formidable challenge in oncology

Sansanima Ltd

Developing in vitro, cell-based assay technologies to replace animal testing.

Atelerix Ltd

Hypothermic gel-based technology to preserve live cells, tissues and viruses at room temperature

Revolver Therapeutics

An University of Bath spinout exploring new potential drug candidates for childhood glioma.

Ascend Bio Ltd

A Company Pioneering Cell Therapy Cures

Vesynta Ltd

Developing a clinical decision modelling software leveraging AI to maximise therapeutic potential and de-risk drug development.

Clotprotect Therapeutics

Developing a first-in-class small molecule direct plasmin inhibitor for intravenous administration.

Stratosvir

Developing viral immunotherapy for late-stage cancer by enabling intravenous delivery and facilitating multiple dosing.

CamGene Therapeutics

A pre-seed company aiming to transform the treatment of hearing loss.

CardiaTec Biosciences

Applying artificial intelligence on large-scale multiomic data to develop the next generation of cardiovascular disease drug targets

Alevin Therapeutics

Developing a platform of novel small molecule RGD integrin inhibitors with superior drug-like qualities.

Neurocentrx Pharma Ltd

Developing medicines to treat patients with neurological conditions.

Xploro

Using artificial intelligence, augmented reality and games to reduce stress and anxiety and improve patient outcomes

Neuroute

AI clinical development platform that enables transformative medicines

BiVictriX

Leveraging frontline clinical experience for the development of next generation cancer therapies

Sanome

An AI powered clinical decision support to improve patient outcomes

Monument Therapeutics

Bringing Precision Medicine to Neuroscience Drug Development

Stingray Bio

By targeting neglected but essential cancer kinases, the Company aims to generate next-generation oncology therapeutics for cancer patients.

Kuano

De-risking and accelerating drug discovery by combining quantum and AI

Spirea

Linking targeted cancer therapy to better patient outcomes

Tay Therapeutics

Because skin matters

Cortirio

Portable diagnosis of brain injuries

Stemnovate

Drug Toxicity Testing

Arecor

Developing ultra rapid and ultra concentrated insulin

NeoPhore

Discovering novel medicines that uses the bodies immune system to fight cancer

Opal Oncology

New therapeutics to treat brain cancer

Sentinel Oncology

New medicines to treat cancer indications and rare diseases

Talisman Therapeutics

Human stem cell drug discovery services

Five Alarm Bio

Seeking to develop drugs to slow down the ageing process

Oppilotech

New antibiotics to overcome drug resistance based on proprietary machine learning platform

PhoreMost

New drug target identiﬁcation platform

Privitar

Data Privacy. Secondary, Series, Led by Warburg Pincus (~20X)

Acacia Pharma

Novel medicine to support cancer therapy IPO MAR 2018 (EURONEXT: ACPH.BR (~9X))

PharmEnable

Diverse database of synthesiable compounds used to ﬁnd start points for new research programmes

Qkine

Re-defining growth factor and cytokine quality to advance stem cell, organoid and regenerative medicine

Heartfelt Technologies

Automatic, Non-Contact Home Heart Failure Monitoring For The Casually Compliant Patient

Neurofenix

Developing medical devices for the upper limb rehabilitation of stroke patients

Turbine

Turbine models how cancer works on the molecular level and tests millions of potential drugs on it with artiﬁcial intelligence

Pencil Biosciences

Next generation gene editing technology

AI VIVO

Intelligent Systems Pharmacology powered by Artiﬁcial Intelligence. Breakthrough information against COVID-19

Small Pharma Limited

Use known actives in certain recreational drugs to treat mental health conditions

ViaNautis

The 'bionic nanoparticle' company using Polynaut for Pharma services and live cell imaging

Metrion Biosciences

Electrophysiology screening services to support client medicinal chemistry optimisation programmes

DeepMatter

Digitizing pharmaceutical chemistry (AIM: DMTR.L)

Oxford Drug Design

Machine learning platfrom used to ﬁnd ligands for Aminoacyl tRNA Synthetases

Exonate

Novel medicine as a drop to target disease of the eye

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)

our full portfolio

Order

Status

Therapeutics Area

Investment Type

1 – You could lose all the money you invest